Vivek Rao
Scientist-F |
Decision Unit 6: Infectious Diseases Biology
Professor |
Academy of Scientific and Innovative Research
Vivek Rao's lab focuses on understanding innate immune response pathways in tuberculosis. His research emphasizes host-directed therapies by targeting harmful host pathways and improving infection outcomes.
Specific Interests
- Innate immune response dynamics in mycobacterial infections
- Host-directed therapeutic strategies for tuberculosis
- Macrophage metabolism and inflammation regulation
His work has highlighted the importance of lysosomal pathways in Mycobacterium tuberculosis infection and demonstrated novel therapeutic strategies using FDA-approved drugs. His lab also studies the immuno-metabolic regulation of macrophage function and inflammation.
Selected Publications
All Citations →- The antidepressant sertraline provides a novel host directed therapy module for augmenting TB therapy. Shankaran D, Singh A, Dawa S, Arumugam P, Gandotra S, Rao V. Elife. 2023 Jan 11;12:e64834.
- The mitochondrial gene-CMPK2 functions as a rheostat for macrophage homeostasis. Arumugam P, Chauhan M, Rajeev T, Chakraborty R, Bisht K, Madan M, … Rao V. Front Immunol. 2022 Nov 14;13:935710.
- Identification and characterization of novel infection associated transcripts in macrophages. Arumugam P, Singla M, Lodha R, Rao V. RNA Biol. 2021 Nov 12;18(sup2):604–611.
- The MmpS6-MmpL6 Operon Is an Oxidative Stress Response System Providing Selective Advantage to Mycobacterium tuberculosis in Stress. Arumugam P, Shankaran D, Bothra A, Gandotra S, Rao V. J Infect Dis. 2019 Jan 9;219(3):459–469.
- A novel mutation alters the stability of PapA2 resulting in the complete abrogation of sulfolipids in clinical mycobacterial strains. Panchal V, Jatana N, Malik A, Taneja B, … Rao V. FASEB Bioadv. 2019 Apr 10;1(5):306–319.